Login to Your Account



Other News To Note


Friday, November 8, 2013
• Quest Pharmatech Inc., of Edmonton, Alberta, said it continued an exclusive license agreement with Stanford University to develop and market anti-MUC1 IgE technology for the treatment of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription